Targets to Therapeutics in Pancreatic Cancer

胰腺癌的治疗目标

• 批准号: 7271112
• 负责人: DANIEL D VON HOFF
• 金额: $ 312.97万
• 依托单位: TRANSLATIONAL GENOMICS RESEARCH INST
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-30 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7271112
• 关键词: Targets; Therapeutics; Pancreatic; Cancer

DESCRIPTION (provided by applicant): Pancreatic cancer is now the fourth leading cause of death from cancer in women and men in the United States. New, innovative approaches to the prevention and treatment of pancreatic cancer are sorely needed. This Program Project Grant (P01) application in pancreatic cancer takes up that challenging need, building on a strong foundation of interest and expertise in pancreatic cancer and in drug development at the Arizona Cancer Center (AZCC) at the University of Arizona. The central theme and goal of this P01 is to speed delivery into the clinic of new therapeutic agents against new targets in pancreatic cancer. The goal of this P01 is that in each year of this P01, we will deliver a new agent into clinical trials in patients with pancreatic cancer, which hits a target discovered and validated in one of the projects of this P01. This P01 application represents a revised application that we feel is an improved, more focused effort against the disease. Responses to each of the critiques are presented in the beginning of each section of the application. Two years ago, the AZCC formed the Sydney Salmon Pancreatic Cancer Team (named after the founding director of the AZCC who passed away from the disease). The team has built an infrastructure of investigators (established and new, in basic, translational, and clinical research), developed a patient base, begun a series of clinical trials, and created an ongoing forum for communicating new research initiatives and findings. In addition, Dr. .Von Hoff, the principal investigator for this application, has stepped down from the Directorship of the Arizona Cancer Center to devote full time to this effort. Our approach to make a difference against pancreatic cancer focuses on the development of innovative, translational ways to tackle the disease. Out of that groundwork effort comes this P01 application focusing on pancreatic cancer. As we hope the reviewers will see, our team has already made substantial progress in identifying new targets in and indeed new approaches to pancreatic cancer. This P01 application focuses that ongoing work and translates that work into new therapeutics that will be brought into patients. This P01 contains three translational research projects whose collective aims are to develop new therapeutics for patients with pancreatic cancer. These related Projects include: (1) Treatment of Hypoxia Resistance in Pancreatic Cancer; (2) Method to Eliminate Pancreatic Cells with Specific Patterns of Mutations/Deletions; and (3) Validation of Amplified Genes in Pancreatic Cancer: New sensitizing Targets for Improved Gemcitabine Therapy. Each project already has some leads and each project is designed to maximize translational potential. As will be seen in the application, the Projects are highly integrated so there is the highest probability we can bring that one therapeutic to the clinic each year. The projects are supported by four highly-integrated shared services (cores): (1) Pancreatic Cancer Biospecimens Repository; (2) Pattern Analysis and Computational Biology Core; (3) Drug Development Core; and (4) Evaluation and Administration Core. These cores provide material, informatic, development and administrative support for the projects. Since we are blessed by having such excellent shared services at the Arizona Cancer Center (AZCC), the cores in this proposed P01 are designed to utilize those cores and therefore for this application we are only asking for resources to provide the services that are over an above the services that can be provided by these AZCC cores. In addition, both internal and external scientific advisory boards are included in the P01 to assure maximum input into the science and into the execution of the Projects. The overall goal of this P01 is the delivery into the clinic one new therapeutic agent against a new target in pancreatic cancer each year of the P01. We feel this effort, with new approaches to pancreatic cancer, concentrated in a P01, has a chance to make an impact on the disease.

描述（由申请人提供）：胰腺癌目前是美国女性和男性癌症死亡的第四大原因。迫切需要新的、创新的方法来预防和治疗胰腺癌。该项目在胰腺癌方面的项目补助金 (P01) 申请满足了这一具有挑战性的需求，建立在亚利桑那大学亚利桑那癌症中心 (AZCC) 对胰腺癌和药物开发的兴趣和专业知识的坚实基础上。 P01 的中心主题和目标是加快针对胰腺癌新靶点的新治疗药物的临床交付。本 P01 的目标是，在本 P01 的每一年，我们都会向胰腺癌患者提供一种新药物进行临床试验，该药物能够达到本 P01 项目中发现和验证的目标。 这个 P01 应用程序代表了一个修订后的应用程序，我们认为它是针对该疾病的改进、更集中的努力。对每项批评的回应都在申请的每个部分的开头给出。 两年前，AZCC 成立了悉尼鲑鱼胰腺癌团队（以因病去世的 AZCC 创始主任的名字命名）。该团队建立了研究人员基础设施（基础研究、转化研究和临床研究方面的现有研究人员和新研究人员），开发了患者基础，开始了一系列临床试验，并创建了一个持续的论坛来交流新的研究计划和发现。此外，该应用的首席研究员 .Von Hoff 博士已辞去亚利桑那州癌症中心主任职务，全职投入这项工作。我们对抗胰腺癌的方法侧重于开发创新的转化方法来应对这种疾病。在这些基础工作的基础上，我们推出了专注于胰腺癌的 P01 应用程序。正如我们希望审稿人看到的那样，我们的团队在确定胰腺癌的新靶点和新方法方面已经取得了实质性进展。该 P01 应用程序重点关注正在进行的工作，并将其转化为将带给患者的新疗法。 该 P01 包含三个转化研究项目，其共同目标是为胰腺癌患者开发新疗法。这些相关项目包括：（1）胰腺癌耐缺氧的治疗； (2)消除具有特定突变/缺失模式的胰腺细胞的方法； (3) 胰腺癌中扩增基因的验证：改进吉西他滨治疗的新敏化靶点。每个项目都已经有一些线索，并且每个项目都旨在最大限度地发挥转化潜力。正如在申请中所看到的，这些项目是高度集成的，因此我们每年将一种治疗方法引入诊所的可能性最高。 这些项目由四个高度集成的共享服务（核心）支持：（1）胰腺癌生物样本库； (2)模式分析与计算生物学核心； (3) 药物开发核心； (4) 评估与管理核心。这些核心为项目提供物质、信息、开发和行政支持。 由于我们有幸在亚利桑那癌症中心 (AZCC) 拥有如此出色的共享服务，因此拟议的 P01 中的核心旨在利用这些核心，因此对于此应用程序，我们仅要求提供超出这些 AZCC 核心可以提供的服务的资源。此外，P01 中还包括内部和外部科学顾问委员会，以确保对科学和项目执行的最大投入。 P01 的总体目标是每年向临床提供一种针对胰腺癌新靶点的新治疗药物。我们认为，这项努力，通过针对胰腺癌的新方法（集中在 P01），有机会对该疾病产生影响。